$136 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 35 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AADI BIOSCIENCES INC | $13,389,670 | -31.8% | 1,849,402 | 0.0% | 9.86% | -18.3% | ||
BLU | BELLUS HEALTH INC | $4,554,000 | -12.4% | 632,500 | 0.0% | 3.36% | +4.9% | |
GHRS | GH RESEARCH PLCordinary shares | $1,943,568 | -17.8% | 243,250 | 0.0% | 1.43% | -1.6% | |
IOVA | IOVANCE BIOTHERAPEUTICS INC | $938,734 | -4.4% | 153,639 | 0.0% | 0.69% | +14.6% | |
EYPT | EYEPOINT PHARMACEUTICALS INC | $891,984 | -16.0% | 303,396 | 0.0% | 0.66% | +0.6% | |
PMVP | PMV PHARMACEUTICALS INC | $736,827 | -45.2% | 154,471 | 0.0% | 0.54% | -34.3% | |
HZNP | HORIZON THERAPEUTICS PLC | $654,840 | -4.1% | 6,000 | 0.0% | 0.48% | +14.8% | |
KNTE | KINNATE BIOPHARMA INC | $31,250 | +2.5% | 5,000 | 0.0% | 0.02% | +21.1% | |
NUVBWS | NUVATION BIO INC*w exp 07/07/2027 | $10,900 | -17.0% | 90,832 | 0.0% | 0.01% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
IRIDEX CORP | 20 | Q3 2019 | 8.1% |
ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
VERACYTE INC | 19 | Q3 2019 | 10.1% |
ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.